Novartis malaria drug seen safe, effective: FDA staff
WASHINGTON (Reuters) - Data shows Novartis AG's combination malaria drug Coartem appears to work and causes few serious side effects, U.S. Food and Drug Administration regulatory staff said in documents released on Monday.<div class="feedflare">
<img src="http://feedproxy.google.com/~f/reuters/healthNews?d=41" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=BBPVH67k) <img src="http://feedproxy.google.com/~f/reuters/healthNews?i=YBQQuQrF" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=YBQQuQrF) <img src="http://feedproxy.google.com/~f/reuters/healthNews?i=iTbtnIpS" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=iTbtnIpS)
</div><img src="http://feedproxy.google.com/~r/reuters/healthNews/~4/MPFa-ac_45U" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/healthNews/~3/MPFa-ac_45U/idUSTRE4B04G020081201